Sembragiline
An investigational drug for neurodegenerative diseases
Sembragiline is a monoamine oxidase B (MAO-B) inhibitor that has been investigated for its potential use in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is a selective and reversible inhibitor, which means it specifically targets the MAO-B enzyme without permanently deactivating it.
Mechanism of Action[edit | edit source]
Sembragiline works by inhibiting the activity of the MAO-B enzyme. MAO-B is responsible for the breakdown of dopamine in the brain. By inhibiting this enzyme, sembragiline increases the availability of dopamine, which is a neurotransmitter that plays a key role in regulating mood, cognition, and movement. This mechanism is particularly beneficial in neurodegenerative diseases where dopamine levels are typically reduced.
Clinical Development[edit | edit source]
Sembragiline has undergone several clinical trials to assess its efficacy and safety in patients with neurodegenerative diseases. Early studies have shown that it is well-tolerated and may have beneficial effects on cognitive function and motor symptoms. However, further research is needed to fully establish its therapeutic potential and to determine the optimal dosing regimen.
Potential Benefits[edit | edit source]
The potential benefits of sembragiline in treating neurodegenerative diseases include:
- Improved cognitive function in patients with Alzheimer's disease.
- Reduction in motor symptoms in patients with Parkinson's disease.
- Neuroprotective effects that may slow the progression of these diseases.
Side Effects[edit | edit source]
As with any medication, sembragiline may cause side effects. Common side effects observed in clinical trials include:
- Nausea
- Headache
- Dizziness
- Insomnia
It is important for patients to discuss potential side effects with their healthcare provider before starting treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on further understanding the long-term effects of sembragiline, its impact on disease progression, and its potential use in combination with other therapies. Researchers are also exploring its effects on other neurodegenerative conditions beyond Alzheimer's and Parkinson's diseases.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
